Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD.

Seraxis to provide oral update on its pancreatic organoidcandidate for functional cure of T1D at the 59 th AnnualMeeting of the EASD Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology forthe production of therapeutic pancreatic organoids from pancreas-derived stem cells,as well as review initial diabetes model data of functional cure of Type 1 Diabetes Seraxis’ presentation entitled “Stem-cell Derived Islets for Treating Diabetes” will bedelivered in the session entitled Transplantation of Islet and Stem Cells Today andTomorrow Germantown, MD, September 21, 2023. Seraxis, Inc., a regenerative medicine companydeveloping a pancreatic organoid cure to transform the lives of patients with Type 1 andinsulin-requiring Type 2 diabetes, today announced that the European Association for the Studyof Diabetes has selected Seraxis to present an oral discussion entitled “Stem-cell derived isletsfor Treating Diabetes” at the EASD 59 th Annual Meeting in Hamburg. Seraxis CEO Dr. WilliamRust will be speaking in the 12:30 – 1:30pm (CET) Short Oral Event A on Tuesday, October 3. The accepted abstract summarizes Seraxis’ development of a novel human immortal stem cellline generated from a consented donor pancreas that differentiates to organoids resemblinghuman islets in morphology, distribution and function of hormone expressing cells. In themouse model of STZ induced Type 1 Diabetes, organoid implantation resulted in glycemiccontrol 3-4 weeks post-implant. This is the first description of a novel, non-embryonic, non-iPSCcell bank with the potential for clinical benefit. ABOUT SERAXIS Seraxis is bringing transformative cures to millions of people worldwide struggling with themanagement and life-threatening complications of insulin-dependent diabetes. Seraxis’ lead program, SR-02, is a novel, off-the-shelf pancreatic organoid therapy slated toenter clinical testing with immunosuppressive therapy in 2024 in patients with severe recurrenthypoglycemia. A follow-on diabetes program, SR-03, is a version of the Seraxis organoid alteredto be unrecognized by the immune system for the broader indication of insulin-dependentpatients without chronic immune suppression. Seraxis’ underlying proprietary technology enables the creation of a pipeline of novel stemcell-derived therapies originating from single donated organs for other indications. The company’s lead therapeutic program, SR-02, is manufactured from a stem cell line derived froma human donor pancreas. These cells preferentially re-differentiate into organoids containing allthe endocrine cells of the native pancreatic islet, and with safety, potency, and manufacturingadvantages over embryonic and induced pluripotent stem cells. Seraxis manufactures its best-in-class therapeutic organoids using scalable, clinically compliantprocesses in its cGMP facility located in Maryland’s I-270 Biotech Corridor. For more information, please visit www.seraxis.com. Contact:Ted Hibben, [email protected]

The release as fetched from its publisher. seraxis.com ↗